Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Eckhardt

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignanciesC D Britten, E K Rowinsky, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodiumS G Eckhardt, H A Burris, J R Eckardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumorsS G Diab, S D Baker, A Joshi, et al.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignanciesM Hidalgo, M A Villalona-Calero, S G Eckhardt, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenograftsA Capasso, J Lang, T M Pitts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Accident; Analysis and Prevention|November 5, 2025
The Manchester driving behavior questionnaire (DBQ) integrating health and technology factors: The DBQ 2025 update with translations in 11 languagesSepideh Harzand-Jadidi, David C Schwebel, Ali Jafari-Khounigh, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignanciesC D Britten, E K Rowinsky, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodiumS G Eckhardt, H A Burris, J R Eckardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumorsS G Diab, S D Baker, A Joshi, et al.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignanciesM Hidalgo, M A Villalona-Calero, S G Eckhardt, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenograftsA Capasso, J Lang, T M Pitts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Accident; Analysis and Prevention|November 5, 2025
The Manchester driving behavior questionnaire (DBQ) integrating health and technology factors: The DBQ 2025 update with translations in 11 languagesSepideh Harzand-Jadidi, David C Schwebel, Ali Jafari-Khounigh, et al.
Pageof 10